基于超微血管成像的血管指数评估成人肝脏脂肪变性:一项可行性研究
前瞻性比较16例正常肝脏与34例脂肪肝的SMI-VI、门静脉流速、肝动脉多普勒参数及血脂和ALT,以MRI-PDFF为参考。SMI-VI与MRI-PDFF呈负相关(r=-0.88),以0.19为最佳截断值诊断≥轻度NAFLD的AUC为0.95、敏感度96%、特异度94%,提示SMI-VI可作为NAFLD筛查的潜在替代标志物。
要点
- SMI-VI与MRI-PDFF呈负相关(r=-0.88),脂肪含量越高SMI-VI越低。
- 以0.19为截断值,SMI-VI诊断≥轻度NAFLD的AUC为0.95、敏感度96%、特异度94%。
- 肝动脉多普勒参数及甘油三酯在正常与脂肪肝间无显著差异(p>0.05)。
核心结论
- SMI-VI用于评估成人肝脏脂肪变性具有可行性,是NAFLD筛查的潜在替代标志物。
研究设计与样本
- 前瞻性可行性研究,纳入16例正常肝脏和34例脂肪肝,以MRI-PDFF为参考标准,比较SMI-VI、门静脉流速、肝动脉多普勒参数及血清脂质和ALT。
关键影像表现/征象
- SMI-VI定义为感兴趣区内彩色像素与总像素之比。
- 正常肝脏(MRI-PDFF<5%)与脂肪肝(MRI-PDFF≥5%)的SMI-VI差异有统计学意义(p<0.02)。
诊断标准与关键数值
- 以0.19为最佳截断值,SMI-VI诊断≥轻度NAFLD(MRI-PDFF≥5%)的AUC为0.95、敏感度96%、特异度94%。
- SMI-VI与MRI-PDFF呈负相关(r=-0.88)。
临床应用与阅片要点
- SMI-VI可作为NAFLD筛查的潜在替代标志物,但原文未据此给出具体阅片建议。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
The aim of the study was to assess the feasibility of using a superb microvascular imaging-based vascular index (SMI-VI) for evaluating adult hepatic steatosis. We prospectively compared liver parenchyma SMI-VI (color pixels/total pixels in the region of interest), portal vein velocity, hepatic artery Doppler parameters (peak systolic velocity, end diastolic velocity, resistive index) and serum lipid and alanine aminotransferase (ALT) levels between 16 normal livers and 34 steatotic livers using magnetic resonance imaging-proton density fat fraction (MRI-PDFF) as the reference. On the basis of a two-tailed t-test, differences in SMI-VI, portal vein velocity, MRI-PDFF and ALT between normal (MRI-PDFF <5%) and steatotic (MRI-PDFF ≥5%) livers were statistically significant (p < 0.02), whereas hepatic artery Doppler parameters and triglyceride levels were not (p > 0.05). We observed an inverse correlation of SMI-VI with MRI-PDFF (r = -0.88). With 0.19 as the best cutoff value, the area under the receiver operating characteristic curve, sensitivity and specificity of SMI-VI for determining ≥mild (MRI-PDFF ≥5%) non-alcoholic fatty liver disease (NAFLD) were 0.95, 96% and 94%, respectively. Our results indicate the feasibility of using SMI-VI to assess adult hepatic steatosis. SMI-VI is a potential surrogate marker in the screening for NAFLD.
引用
- Gao, King, Chatterji, et al. Superb Microvascular Imaging-Based Vascular Index to Assess Adult Hepatic Steatosis: A Feasibility Study. Ultrasound Med Biol. 2021. PMID: 34872787. doi:10.1016/j.ultrasmedbio.2021.11.002
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。